GEN.WAR Genomed S.A.
- Market cap
- PLN 49.2M
- P/E
- 13.3x
- P/B
- 4.24x
- ROE
- 6.6%
- Dividend yield
- 2.25%
- Fundamental score
- 1.6/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is GEN.WAR undervalued?
Graham numberGEN.WAR trades 58.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genomed S.A. fundamental analysis
8 of 22 checks passedROE 0/2
Low return on equity (6.6%), below 10%.
ROA 0/1
Return on assets (5.0%) is below the industry median (5.5%).
Profit Consistency 1/2
Profitable for 4 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (223.0%) is above the industry median (33.8%).
Revenue Growth 2/2
Revenue grew 12.5% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
EBIT is 75.2x against interest expense, well covered.
PE vs Market 0/1
PE (13.4x) is above the market median (11.6x).
PE vs Industry 0/1
PE (13.4x) is above the industry median (11.6x).
PBV 0/1
Price to book (4.3x) is above the industry median (2.5x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 57.0, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (2.2%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 32.5%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Genomed S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genomed S.A.
Genomed Spólka Akcyjna provides DNA and RNA sequencing and analysis and diagnostics services for congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company's diagnostic services include DNA isolation, PCR amplification of chosen DNA regions, comparison of the sequences, and interpretation of the results by diagnosticians. It also provides various…
Full company profileGenomed S.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genomed S.A. annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 20.5M | 22.5M | 23.0M | 29.1M | 27.8M |
| Gross Profit | 12.2M | 14.1M | 14.5M | 19.3M | 18.1M |
| Operating Income | 357K | 1.24M | 1.20M | 4.08M | 1.19M |
| EBITDA | 1.09M | 1.67M | 1.96M | 4.84M | 1.99M |
| Net Income | 338K | 926K | 1.11M | 3.40M | 821K |
| EPS | 0.26 | 0.70 | 0.84 | 2.70 | 0.65 |
| Balance Sheet | |||||
| Total Assets | 10.4M | 12.1M | 12.4M | 16.5M | 16.3M |
| Total Liabilities | 1.24M | 2.06M | 1.68M | 2.41M | 3.88M |
| Shareholders' Equity | 9.13M | 10.1M | 10.7M | 14.1M | 12.4M |
| Cash & Short-term Investments | 3.49M | 5.26M | 5.24M | 6.10M | 7.33M |
| Cash Flow | |||||
| Operating Cash Flow | -356K | 1.97M | 1.64M | 3.23M | 2.63M |
| Capital Expenditure | 246K | 204K | 1.67M | 1.13M | 184K |
| Free Cash Flow | -602K | 1.76M | -27.0K | 2.11M | 2.45M |
| Ratios | |||||
| ROE | 3.7% | 9.2% | 10.3% | 24.1% | 6.6% |
| ROA | 3.3% | 7.6% | 8.9% | 20.6% | 5.0% |
| Net Profit Margin | 1.7% | 4.1% | 4.8% | 11.7% | 3.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Genomed S.A. dividends
- Dividend yield
- 2.25%
- Forward dividend
- 1.50 PLN
- Payout ratio
- 32.5%
- Ex-dividend date
- Jul 6, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | PLN 1.11M | 0.88 | 32.5% |
| 2024 | - | - | - |
| 2023 | PLN 204K | 0.15 | 22.0% |
| 2022 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Genomed S.A.
- Insiders 85.93%
- Institutions 0.00%
- Public & others 14.07%
- Shares outstanding 1.32M
Genomed S.A. company profile
- Company name
- Genomed S.A.
- Ticker
- GEN.WAR
- ISIN
- PLGNOMD00024
- Exchange
- Warsaw Stock Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 58
- Fiscal year end
- December
- Address
- ul. Ponczowa 12, Warsaw, Poland, 02-971
- Phone
- 48 22 644 6019
- Website
- genomed.pl
About Genomed S.A.
Genomed Spólka Akcyjna provides DNA and RNA sequencing and analysis and diagnostics services for congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company's diagnostic services include DNA isolation, PCR amplification of chosen DNA regions, comparison of the sequences, and interpretation of the results by diagnosticians. It also provides various types of DNA sequence analysis, including polymorphism analysis or sequencing of phage genetic material or bacteria genomes; and next-generation sequencing and genetic counseling services. In addition, the company offers DNA oligonucleotides synthesis, RNA oligonucleotides and peptide synthesis, various nucleotide modifications, and the 4LAB automated pipetting workstation, as well as laboratory equipment through e-store. It serves scientific institutes, universities, hospitals, and biotechnological and pharmaceutical companies, as well as healthcare networks and individual customers. The company was founded in 2007 and is headquartered in Warsaw, Poland.
Genomed S.A. management
5- Dr. Anna Boguszewska-Chachulska Ph.D.Co-Founder, President of the Management Board & CEO
- Dr. Andrzej Henryk PaluchaCo-Founder & Member of Management Board
- Ms. Iwona WachCo-Founder & Member of the Management Board
- Ms. Anna Piotrowska-MietelskaMember of Management Board
- Mr. Lukasz BrejnakowskiMember of Management Board